Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Switch Obstacles In Europe Threaten OTC Industry Growth – GSK Exec

This article was originally published in The Tan Sheet

Executive Summary

European perceptions that OTC status increases safety risks hinders switch applications, GSK exec Scarlett-Smith contends. He argues OTC buyers are health conscious, adverse events are not isolated to OTCs and despite the centralized switch process, members retain decentralized OTC policies.

You may also be interested in...



European Countries Urged To Boost OTC Profile In Health Care Systems

EU Health Commissioner John Dalli expects the region’s growing health care budgets and economic crisis to lead governments to restructure and impose more responsibility on consumers for health care costs. A self-medication working group launched in France will look at easing Rx-to-OTC switches.

OTC Growth Will Not Find A Friend In Europe’s Financial Upheaval

As economic conditions tighten in Europe, former Pfizer exec Cavan Redmond expects consumers will spend less on OTCs while increasing their scrutiny of products and prices. Difficult economic conditions sharpen the constant necessity for OTC firms generate growth, he says.

European Countries Urged To Boost OTC Profile In Health Care Systems

EU Health Commissioner John Dalli expects the region’s growing health care budgets and economic crisis to lead governments to restructure and impose more responsibility on consumers for health care costs. A self-medication working group launched in France will look at easing Rx-to-OTC switches.

Related Content

Topics

UsernamePublicRestriction

Register

ID1125791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel